Chiusura precedente | 255,60 |
Aperto | 255,20 |
Denaro | 249,35 x 20000 |
Lettera | 249,90 x 9000 |
Min-Max giorno | 250,00 - 256,05 |
Intervallo di 52 settimane | 196,60 - 306,00 |
Volume | |
Media Volume | 600 |
Capitalizzazione | 134,255B |
Beta (5 anni mensile) | 0,60 |
Rapporto PE (ttm) | 21,43 |
EPS (ttm) | 11,68 |
Prossima data utili | 02 mag 2024 |
Rendimento e dividendo (futuro) | 8,29 (3,24%) |
Data ex dividendo | 16 mag 2024 |
Stima target 1A | N/D |
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery